Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004699 | 0.91 | MRGPRX4 (0.43) | MRGPRX4ALOX5ALOX5APMAOBCYP11B1 | |
| SCHEMBL18004691 | 0.90 | NR4A2 (0.44) | MAOBCYP11B1CYP11B2GRM5DHFR | |
| SCHEMBL18004687 | 0.89 | NR4A2 (0.45) | MRGPRX4MAOBCYP11B1CYP4F2CYP4A11 | |
| SCHEMBL18004697 | 0.89 | MRGPRX4 (0.46) | MRGPRX4MAOBCYP11B1CYP11B2CYP4F2 | |
| SCHEMBL18005970 | 0.88 | NR4A2 (0.46) | MAOBCYP11B1CYP11B2CNR1 | |
| SCHEMBL18006254 | 0.88 | FFAR1 (0.45) | MAOBCYP11B1CYP11B2GRM5CYP4F2 | |
| SCHEMBL18006249 | 0.88 | RAB9A (0.44) | MRGPRX4MAOBCYP11B1CYP11B2CYP4F2 | |
| SCHEMBL18006273 | 0.88 | MRGPRX4 (0.46) | MRGPRX4CYP11B1CYP11B2CYP4F2CYP4A11 | |
| SCHEMBL18004433 | 0.87 | NR4A2 (0.47) | MAOBCYP11B1CYP11B2GRM5DHFR | |
| SCHEMBL26070591 | 0.87 | CNR1 (0.39) | MRGPRX4CYP11B1CYP11B2CNR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MRGPRX4 4062/4885ALOX5 3378/4885ALOX5AP 3601/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | MRGPRX4 4062/4885ALOX5 3378/4885ALOX5AP 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.